Chicken Infectious Anaemia Virus

Overview and Taxonomy of Chicken Infectious Anaemia Virus

Chicken infectious anaemia virus (CIAV), also historically referred to as chicken anaemia virus (CAV) or the causative agent of chicken anaemia agent (CAA), represents one of the most economically significant and biologically distinctive pathogens affecting global poultry production [11, 14, 18]. First identified in 1979 by Yuasa and colleagues in Japan during investigations of Marek’s disease outbreaks, CIAV was recognized as a novel agent capable of inducing severe anaemia, generalized lymphoid atrophy, and high mortality in young chickens [11, 18]. Since its initial characterization, CIAV has been documented across virtually all major poultry-producing regions worldwide, establishing itself as a ubiquitous and resilient pathogen that poses persistent challenges to both commercial and backyard poultry operations [1, 5, 6, 17]. The virus is now understood to be the smallest known DNA virus infecting chickens, with a virion diameter ranging from approximately 19.1 to 26.5 nm, and it exhibits a non-enveloped icosahedral capsid structure that contributes substantially to its remarkable environmental stability and resistance to conventional disinfection protocols [11, 14, 18].

Taxonomic Classification and Genomic Organization

The taxonomic placement of CIAV has undergone significant refinement as molecular characterization techniques have advanced. CIAV is currently classified within the genus Gyrovirus, family Anelloviridae, a taxonomic assignment that reflects its unique genomic features and evolutionary relationships [11, 14]. Historically, the virus was placed within the family Circoviridae due to its small, circular, single-stranded DNA genome and non-enveloped virion structure [14, 18]. However, subsequent phylogenetic analyses revealed that CIAV and related gyroviruses form a distinct lineage separate from true circoviruses, leading to their reclassification into the family Anelloviridae [11]. This taxonomic distinction is critical for understanding the virus’s replication strategy, evolutionary dynamics, and pathogenic mechanisms. The CIAV genome consists of a negative-sense, single-stranded, circular DNA molecule of approximately 2.3 kilobases (2.3 kb), making it one of the smallest known viral genomes capable of autonomous replication in avian hosts [11, 18, 19].

The compact genome of CIAV encodes three major viral proteins, each with distinct and essential functions in the viral life cycle and pathogenesis. The largest protein, VP1 (approximately 51.6 kDa), constitutes the primary structural component of the viral capsid and is the principal target for neutralizing antibodies [11, 18, 19]. VP1 exhibits considerable genetic variability among field isolates, and this diversity serves as the foundation for molecular epidemiological studies and phylogenetic classification of CIAV strains globally [5, 6, 19, 21]. The second protein, VP2 (approximately 24 kDa), is a non-structural protein that possesses dual-specificity phosphatase activity and functions as a scaffolding protein essential for the proper assembly of VP1 into infectious virions [11, 18]. Importantly, the co-synthesis of VP1 and VP2 is required for the production of neutralizing antibodies, highlighting the critical role of VP2 in the immune response to CIAV infection [18]. The third and smallest protein, VP3 (approximately 13.6 kDa), is a non-structural protein known as apoptin, which is the primary mediator of virus-induced apoptosis in infected cells [11, 18, 20]. Apoptin selectively induces programmed cell death in erythrocyte precursors and thymocytes, leading to the characteristic anaemia and immunosuppression that define CIAV pathogenesis [11, 18, 20]. The VP3 protein has garnered significant research interest beyond avian medicine due to its selective ability to induce apoptosis in human tumour cells while sparing normal cells, making it a subject of investigation for potential cancer therapeutic applications [11].

Genetic Diversity and Phylogenetic Classification

The genetic diversity of CIAV is a defining feature of its epidemiology and has been the subject of extensive molecular characterization across multiple continents. Phylogenetic analyses based primarily on the VP1 gene, but increasingly on complete genome sequences, have revealed the existence of multiple distinct genotypes or genogroups that circulate in different geographic regions and poultry production systems [5, 6, 10, 21]. Early classification schemes identified three major genotypes, designated as genotypes I, II, and III, based on VP1 sequence analysis [5, 21]. However, more recent and comprehensive studies have refined this classification to include additional genotypes and sub-genotypes, reflecting the ongoing evolution and diversification of CIAV [5, 10, 21].

In a landmark molecular epidemiological study conducted in China during 2020–2021, Sun et al. [5] analyzed 91 CIAV strains from 17 provinces and demonstrated that the circulating viruses belonged to three genotypes: II, IIIa, and IIIb. Notably, genotype IIIa was identified as the predominant genotype in China, accounting for the majority of field isolates [5]. This finding is consistent with the global emergence of genotype III strains as the most frequently detected lineage in many regions, including Asia, Africa, and the Americas [1, 2, 5, 6]. Whole-genome phylogenetic analysis of 72 of these Chinese strains confirmed that 71 belonged to genotype IIIa, while only one strain clustered with genotype II, underscoring the dominance of genotype III in contemporary CIAV epidemiology [5].

Similarly, a comprehensive investigation of CIAV in Korea by Song et al. [10] characterized 28 complete viral sequences and identified four distinct phylogenetic groups: IIa (7.1%), IIb (32.1%), IIIa (28.6%), and IIIb (32.1%). The major circulating groups were IIb, IIIa, and IIIb, and notably, none of the Korean field isolates clustered with the vaccine strain available in the country, suggesting that vaccine-derived strains are not contributing significantly to the current epidemiological landscape [10]. This study also demonstrated that isolates from different genotypes exhibited varying degrees of pathogenicity in vivo, with the IIIb strain (17AD008) showing the highest virulence, stable cellular adaptability, and elevated virus titers in vitro [10]. These findings indicate that genetic diversity among CIAV isolates is not merely a taxonomic curiosity but has direct implications for viral pathogenesis, transmission dynamics, and vaccine efficacy.

In Taiwan, Ou et al. [21] conducted a large-scale molecular characterization of CIAV from commercial and native chickens between 2010 and 2015, sequencing the coding regions of 51 viruses. Phylogenetic analysis of the VP1 gene revealed that while most Taiwanese CIAVs belonged to genotypes II and III, a subset of isolates clustered into a novel genotype designated as genotype IV [21]. This discovery of a fourth genotype expands the known genetic diversity of CIAV and suggests that the virus continues to evolve through both point mutations and recombination events. Indeed, Ou et al. [21] provided compelling evidence that one Taiwanese isolate in genotype IV originated from an inter-genotypic recombination event between genotype II and III viruses, demonstrating that recombination is an active mechanism driving CIAV evolution. Furthermore, five Taiwanese isolates showed high similarity to vaccine strains 26P4 and Del-Ros, raising concerns about the potential for vaccine-derived viruses to cause clinical disease under field conditions [21].

The genetic diversity of CIAV is not limited to Asia. In Africa, studies from Nigeria have revealed a complex epidemiological picture with multiple genotypes circulating simultaneously. Shettima et al. [1] investigated CIAV in apparently healthy village chickens in Maiduguri, Nigeria, and found that six isolates formed a cluster with strains from India, Thailand, Japan, South India, Taiwan, China, USA, and Australia, while two other isolates (CIAV 14 and CIAV 36) diverged to form a distinct sub-clade with 87% homology to the main cluster. More strikingly, two additional Nigerian isolates (CIAV 79 and CIAV 39) exhibited only 52% and 57% homology, respectively, with the main cluster, forming a separate clade that may represent a unique African lineage [1]. This remarkable genetic divergence within a single geographic region underscores the need for continued molecular surveillance to track the emergence and spread of novel CIAV variants.

Adedeji et al. [2] further characterized Nigerian CIAV strains from poultry flocks co-infected with Marek’s disease virus and identified both genotype II and genotype III viruses that clustered with isolates from Cameroon and China. The presence of multiple genotypes in Nigerian poultry populations suggests that the virus has been circulating in the region for an extended period, allowing for substantial genetic diversification [1, 2]. Similarly, in Vietnam, Huynh et al. [6] demonstrated that all CIAV isolates from northern Vietnam belonged to genogroups G2 and G3 (corresponding to genotypes II and III), and critically, none of the Vietnamese strains possessed amino acid substitutions associated with attenuation, confirming that field strains were distinct from vaccine-like viruses [6].

Global Distribution and Epidemiological Significance

CIAV exhibits a truly global distribution, with documented presence in virtually every country where poultry production occurs, including both industrialized commercial operations and smallholder village systems [1, 3-6, 17, 21]. The virus’s remarkable environmental stability, resistance to common disinfectants, and ability to be transmitted both vertically (through the egg) and horizontally (through direct contact and fomites) contribute to its widespread and persistent circulation [11, 14, 18]. The World Organisation for Animal Health (WOAH) recognizes CIAV as a significant pathogen affecting poultry health and trade, and the virus is included in the WOAH list of notifiable diseases due to its economic impact and potential to compromise food security in regions dependent on poultry production.

The prevalence of CIAV infection varies considerably across geographic regions and production systems, but consistently high seroprevalence rates have been reported worldwide. In Nigeria, Markus et al. [3] reported an overall seroprevalence of 68.2% in chickens from live bird markets in Jos, Plateau State, with significant spatial heterogeneity between Jos North (51.7%) and Jos South (84.3%). This regional variation underscores the importance of localized epidemiological factors, including management practices, biosecurity measures, and environmental conditions, in shaping CIAV transmission dynamics [3]. Similarly, Hassim et al. [4] documented a remarkably high CAV seroprevalence of 87.50% in village chickens in Sri Lanka’s Central Province, with significant associations between seropositivity and flock size as well as veterinary consultation practices. The high seroprevalence in village chickens, which are typically raised under semi-intensive conditions with limited biosecurity, highlights the role of these production systems as reservoirs for CIAV maintenance and spread [4].

In India, multiple studies have confirmed the widespread distribution of CIAV across different states and production systems. Brar et al. [9] detected CIAV in 26.9% of commercial poultry flocks in Haryana using VP2 gene-based PCR, with the partial nucleotide sequences showing 99.2–100% similarity among Indian strains and 97.5–100% similarity to global field strains. Vidya et al. [17] provided the first report of CIAV in Kerala, India, detecting CAV antibodies in 80 out of 92 serum samples (87.0%) by indirect ELISA and confirming CAV infection in 29% of suspected cases by PCR targeting the VP2 gene. These findings indicate that CIAV is endemic in Indian poultry populations, with both serological and molecular evidence supporting its widespread circulation [9, 17]. Krishan et al. [16] further demonstrated the clinical association of CIAV with other infectious poultry diseases in North India and Nepal, detecting CAV genome in 95 out of 185 tissue samples (51.4%) and documenting concurrent infections with infectious bursal disease virus, inclusion body hepatitis, and Marek’s disease virus.

In China, the world’s largest poultry producer, CIAV prevalence rates are among the highest reported globally. Sun et al. [5] conducted a systematic molecular survey across 17 provinces during 2020–2021 and found that 65.4% of clinical samples (375/573) were positive for CIAV by real-time PCR, with regional positivity rates ranging from 46.67% in North China to 81.25% in Central China. This high prevalence, combined with the predominance of genotype IIIa strains, indicates that CIAV is a persistent and active threat to Chinese poultry production [5]. Yao et al. [19] investigated the molecular epidemiology of CAV in sick chickens in China from 2014 to 2015 and reported a CAV-positive rate of 13.30%, with mixed infections (55.56%) being the predominant infection type. The lower detection rate in this earlier study compared to Sun et al. [5] may reflect differences in sampling strategies, diagnostic methods, and the clinical status of the birds examined.

In South America, Jordan et al. [7] documented the presence of CIAV in commercial broiler flocks in Trinidad and Tobago, where mortality rates reached up to 75% in affected flocks. All clinically affected birds tested positive for both CIAV and fowl adenovirus (FAdV), while testing negative for infectious bursal disease virus, highlighting the role of CIAV-induced immunosuppression in precipitating severe secondary viral infections [7]. This study represents the first published report from Trinidad and Tobago on the circulation of pathogenic FAdV strains in combination with CIAV, emphasizing the importance of maintaining high biosecurity standards to prevent the spread of these devastating viruses between farms [7].

Biological and Pathogenic Characteristics

The biological properties of CIAV are intimately linked to its taxonomic classification and genomic organization. As a member of the family Anelloviridae, CIAV shares with other anelloviruses a remarkable resistance to environmental inactivation and chemical disinfection [11, 14, 18]. The non-enveloped virion is resistant to thermal inactivation, treatment with lipid solvents, and many common disinfectants, allowing the virus to persist in poultry houses, equipment, feed, and water for extended periods [11, 14, 18]. This environmental stability is a major factor contributing to the difficulty of eradicating CIAV from infected premises and the high prevalence of the virus in both commercial and backyard poultry operations.

The pathogenesis of CIAV is characterized by a selective tropism for haematopoietic precursor cells in the bone marrow and T-cell precursors in the thymus, leading to severe anaemia and profound immunosuppression [11, 13, 20]. Castaño et al. [20] investigated the tissue tropism of CAV in naturally infected broiler chickens and demonstrated that the virus targets the thymic cortex and bone marrow as the primary sites of replication. Immunohistochemical labelling revealed that VP1 and VP3 antigens were expressed in both the thymus and bone marrow, with VP3 expression being more abundant in other organs, suggesting that VP3-mediated apoptosis may contribute to tissue damage beyond the primary target organs [20]. Importantly, labelling of serial sections showed that CD3+ T lymphocytes are likely responsible for disseminating the virus from the thymus and bone marrow to other organs, and that virus-induced apoptosis, mediated through caspase-3 activation, occurs predominantly in the thymus and bone marrow [20].

The immunosuppressive effects of CIAV are mediated through multiple mechanisms, including the depletion of both CD4+ and CD8+ T lymphocyte populations, downregulation of cytokine expression, and induction of apoptosis in lymphoid and haematopoietic cells [11, 13, 15]. Wani et al. [13] demonstrated that subclinical CIAV infection in 6-week-old SPF chicks resulted in a significant decline in haematocrit values, total leukocyte counts, and peripheral lymphocyte counts by 15 days post-infection, even in the absence of clinical signs. Flow cytometric analysis revealed that the percentages of CD4+CD8- and CD4-CD8+ T cells were significantly decreased in both the spleen and blood of infected chicks, confirming that subclinical infections are indeed immunodepressive [13]. Basaraddi et al. [15] further characterized the immunopathological changes in CIAV-infected chicks and observed downregulation of interleukin (IL)-1β, IL-10, IL-12β, and granulocyte-macrophage colony-stimulating factor (GM-CSF) gene expression, along with depressed cell-mediated immune responses as measured by lymphocyte transformation tests. The severity of these immunopathological changes was age-dependent, with younger chicks exhibiting more pronounced effects [15].

The ability of CIAV to induce apoptosis is mediated primarily by the VP3 protein (apoptin), which triggers programmed cell death in erythrocyte precursors and thymocytes [11, 18, 20]. Latheef et al. [12] evaluated apoptosis in thymocytes of SPF chicks co-infected with CIAV and Marek’s disease virus and found significantly higher levels of caspase-3 release in co-infected groups compared to single infections. The peak caspase-3 activity occurred at 28 days post-infection, and while the CIAV-alone group showed a decline by day 42, the co-infected group maintained significantly elevated levels, indicating that concurrent infections exacerbate CIAV-induced apoptosis and immunosuppression [12].

Implications for Disease Control and Future Research

The taxonomic classification and genetic diversity of CIAV have direct implications for disease control strategies, including vaccine development and diagnostic approaches. Despite the substantial genetic variability observed among field isolates, all CIAV strains identified to date belong to a single serotype, meaning that there are no major antigenic differences that would necessitate serotype-specific vaccines [11, 14]. This serological uniformity suggests that existing vaccines, which are typically based on live-attenuated strains such as 26P4 or Del-Ros, should provide broad protection against diverse genotypes [11, 21]. However, the detection of vaccine-like strains in clinically affected birds in Taiwan raises concerns about the potential for vaccine reversion to virulence or the emergence of vaccine-derived recombinants with altered pathogenic properties [21].

The development of effective vaccination strategies remains a cornerstone of CIAV control, particularly in breeder flocks where the goal is to induce high levels of maternal antibodies that protect progeny during the critical first weeks of life [8, 11, 22]. Rodrigues et al. [22] evaluated the rate of transfer of CIAV maternal antibodies from broiler breeders to their progeny under field conditions and found that breeders vaccinated at 14 weeks of age had antibody titers ranging from 5,051 to 8,660, with an average transfer rate of 63% to progeny. Maternal antibodies lasted up to the second week of the chicks’ life, providing a window of protection during the period of highest susceptibility [22]. Chellappa et al. [8] developed a novel bivalent vaccine candidate using Newcastle disease virus as a vector to deliver the VP2 and VP1 genes of CIAV, demonstrating robust humoral and cell-mediated immune responses in vaccinated chickens. This approach offers the potential for simultaneous protection against both Newcastle disease and chicken infectious anaemia, representing a significant advancement in poultry vaccine technology [8].

The emergence of novel genotypes and the detection of inter-genotypic recombination events underscore the need for ongoing molecular surveillance to monitor the evolution of CIAV and assess

Molecular Pathogenesis and Genetic Variability of Chicken Infectious Anaemia Virus

The molecular pathogenesis of Chicken Infectious Anaemia Virus (CIAV) is a paradigm of viral subversion of the host immune system, driven by a remarkably compact genome that encodes a triad of proteins with distinct and synergistic functions. Understanding the intricate relationship between the virus’s genetic architecture and its pathogenic mechanisms is critical for developing effective control strategies, particularly given the virus’s global distribution and its role as a keystone immunosuppressive pathogen in poultry. The virus, classified within the genus Gyrovirus of the family Anelloviridae [11, 18], is a non-enveloped icosahedron with a diameter of approximately 19–26.5 nm, containing a single-stranded, negative-sense, circular DNA genome of about 2.3 kb [11, 18]. This minimalist genome, the smallest among known avian DNA viruses, belies a sophisticated pathogenic strategy that targets the very cells responsible for both haematopoiesis and adaptive immunity.

Molecular Determinants of Pathogenesis: The Tripartite Genome and Apoptosis

The CIAV genome encodes three major viral proteins: VP1, VP2, and VP3, each playing a non-redundant role in the viral life cycle and disease induction. VP1 (51.6 kDa) is the sole structural capsid protein, responsible for viral attachment, entry, and the elicitation of neutralizing antibodies [11, 18]. Critically, the co-synthesis of VP1 and VP2 is required for the production of neutralizing antibodies, indicating that VP2 (24 kDa), a non-structural protein with dual-specificity phosphatase activity, acts as a scaffold or chaperone for proper VP1 folding and assembly [18]. VP2’s phosphatase activity is also implicated in modulating host cell signalling pathways, though its precise role in pathogenesis remains an area of active investigation.

The most extensively studied pathogenic determinant is VP3 (13.6 kDa), universally known as apoptin. Apoptin is a potent, virus-encoded inducer of apoptosis, and its activity is central to the hallmark lesions of CIAV infection: aplastic anaemia and generalized lymphoid atrophy [11, 18, 20]. Apoptin selectively induces programmed cell death in chicken thymocytes and erythrocyte precursor cells, as well as in a variety of transformed mammalian cell lines, making it a subject of interest in cancer research [27]. The mechanism involves nuclear localization, interaction with cellular proteins like Anaphase-Promoting Complex/Cyclosome (APC/C), and activation of the caspase cascade. The downstream consequence is the massive destruction of haemocytoblasts in the bone marrow and immature T-lymphocytes in the thymic cortex, leading to the characteristic depletion of haematopoietic and lymphoid cells [11, 20]. Immunohistochemical studies of naturally infected broilers have demonstrated that VP3 expression is particularly abundant in the thymic cortex and bone marrow, correlating directly with sites of severe cell depletion and the presence of intranuclear acidophilic inclusion bodies [20]. Furthermore, the apoptotic process is mediated through caspase-3 activation, as demonstrated by co-localization of VP3 and cleaved caspase-3 in serial sections of thymus and bone marrow from infected chicks [20]. This apoptotic pathway is not merely a terminal event; it is a highly efficient mechanism for viral dissemination and immune evasion, as the destruction of immune cells occurs before an effective adaptive response can be mounted.

Immunopathogenesis: T Cell Depletion and Cytokine Dysregulation

The clinical and subclinical manifestations of CIAV infection are a direct consequence of its profound immunosuppressive effects. The virus exhibits a pronounced tropism for primary lymphoid tissues, particularly the thymus and bone marrow, and to a lesser extent, the spleen and bursa of Fabricius [20, 28]. Experimental infections have demonstrated that CIAV replicates to high titres in these tissues, with peak viral loads occurring between 10 and 20 days post-infection (dpi) in lymphoid organs such as the thymus, spleen, and bone marrow, with the highest load often detected in the blood [28].

The most critical immunological consequence is the selective depletion of T-lymphocyte populations. Flow cytometric analysis of chicks experimentally infected with CIAV at six weeks of age (a model for subclinical infection) revealed a significant decrease in both CD4+CD8- (helper) and CD4-CD8+ (cytotoxic) T cells in the spleen and peripheral blood by 15 dpi [13]. This depletion occurs even in the absence of overt clinical signs, underscoring the insidious nature of subclinical CIAV infections, which are far more common in the field than the classic severe anaemia syndrome [13]. The loss of these key T-cell subsets cripples both cell-mediated immunity and the ability to provide effective T-cell help for humoral responses.

This cellular depletion is accompanied by a profound dysregulation of the cytokine network. A landmark study using quantitative real-time PCR demonstrated a significant downregulation of key pro-inflammatory and immunomodulatory cytokines, including interleukin (IL)-1β, IL-10, IL-12β, and granulocyte-macrophage colony-stimulating factor (GM-CSF) in chicks infected at various ages [15]. The downregulation was most pronounced in chicks infected at a younger age (1 day old), correlating with the more severe clinical disease observed in very young birds [15]. Interestingly, while some cytokines like IL-2 are suppressed in splenic tissue, others such as interferon-gamma (IFN-γ) show a biphasic response. IFN-γ levels increase two- to five-fold in the spleen and blood, peaking concurrently with the peak viral load at 10 dpi, before declining [28]. This initial IFN-γ surge may represent a host antiviral attempt, but it is ultimately insufficient to control the infection, and the overall milieu is one of immunosuppression. The net effect is a severely compromised cell-mediated immune (CMI) response, characterized by reduced lymphocytic proliferation activity as measured by the lymphocyte transformation test (LTT) [15]. This CMI suppression is the gateway for the devastating synergistic interactions observed with co-infecting pathogens.

Synergistic Pathogenesis: The Role of CIAV in Co-Infections

The immunosuppression induced by CIAV is not an isolated pathological event; it is a potent amplifier of disease caused by other viral, bacterial, and parasitic agents. This synergistic pathogenesis is a major driver of economic losses in the poultry industry worldwide. The virus’s ability to predispose birds to secondary infections is well-documented across multiple continents and production systems.

Viral Co-Infections: The most clinically significant interactions are with other immunosuppressive and respiratory viruses. Co-infection with Marek’s Disease Virus (MDV) is particularly severe. In experimental settings, chicks co-infected with CIAV and a very virulent MDV (vMDV) exhibited significantly higher levels of apoptosis in thymocytes, as measured by caspase-3 release, compared to chicks infected with either virus alone [12]. The peak of apoptosis was sustained longer in the co-infected group, indicating a synergistic exacerbation of lymphoid destruction [12]. This molecular finding aligns with field observations from Nigeria, where co-infections of CIAV and MDV were detected in 45.8% of tumour samples from suspected MD cases, with 100% of broiler samples showing dual infection [2]. Similarly, in Tamil Nadu, India, concurrent CIAV and MDV infections resulted in more intense pathological changes, including severe organ enlargement and pleomorphic lymphocyte infiltration, compared to CIAV alone [25].

CIAV also profoundly enhances the pathogenesis of respiratory viruses. Pre-infection of specific-pathogen-free (SPF) chicks with CIAV resulted in significantly higher titres of low pathogenic avian influenza (LPAI) H9N2 and infectious bronchitis virus (IBV) in oropharyngeal swabs, tracheas, and kidneys [26]. The immunosuppressed birds developed clinical signs of respiratory disease that were absent in birds infected with the respiratory viruses alone. This enhancement was correlated with elevated levels of IL-6 and IFN-γ, suggesting that CIAV skews the immune response in a way that favours viral replication and pathology [26]. This finding has profound implications for the ecology and evolution of LPAI H9N2, a virus of significant zoonotic concern monitored by the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO). Furthermore, CIAV is a frequent accomplice in outbreaks of inclusion body hepatitis (IBH) and hepatitis-hydropericardium syndrome caused by fowl adenoviruses (FAdV). In Trinidad and Tobago, mortality rates of up to 75% in broiler flocks were linked to co-infections of CIAV with multiple FAdV serotypes (8a, 8b, 9, and 11) [7]. In China, mixed infections of CIAV with chicken parvovirus and FAdV-4 are common, necessitating the development of multiplex diagnostic assays [23].

Bacterial Co-Infections: The immunosuppression also predisposes birds to severe bacterial infections. In layer flocks in India, CIAV was found co-infected with Clostridium perfringens, Staphylococcus aureus, and Escherichia coli, leading to gangrenous dermatitis (GD) [25]. The pathological picture in these cases was dominated by vascular changes, congestion, and the presence of bacterial clusters in organs, indicative of a septicemic state driven by the loss of immune surveillance [25]. Concurrent infections with CIAV and Infectious Bursal Disease Virus (IBDV) are also highly prevalent, with a seroprevalence of 32.7% for dual infection reported in a multi-species study in Nigeria, further compounding the immunosuppressive burden on the bird [24].

Genetic Variability: Global Genotypes and Emerging Lineages

Despite the absence of distinct serotypes, CIAV exhibits remarkable genetic diversity, which has direct implications for its pathogenesis, transmissibility, and potential for immune escape [11, 14]. This diversity is primarily driven by point mutations and recombination events, particularly within the hypervariable region of the VP1 gene, which encodes the capsid protein and is the primary target for neutralizing antibodies [11, 19, 21].

Phylogenetic analyses based on the complete genome and the VP1 gene have consistently classified global CIAV strains into distinct genotypes, with the nomenclature evolving as new data emerges. Early classifications defined three major genogroups, but more recent, large-scale sequencing efforts have refined this. A comprehensive study of 91 Chinese CIAV strains circulating during 2020–2021 identified three genotypes: II, IIIa, and IIIb, with genotype IIIa being the predominant circulating lineage in China [5]. Similarly, a Korean study of 28 complete CIAV sequences revealed a more complex landscape, dividing isolates into four groups: IIa (7.1%), IIb (32.1%), IIIa (28.6%), and IIIb (32.1%), with no strains clustering with the Korean vaccine strain [10]. This indicates that field strains are genetically distinct from vaccine viruses, a finding echoed in Vietnam, where all field isolates lacked the amino acid substitutions associated with attenuation and grouped separately from vaccine-like strains in genogroups G2 and G3 [6].

The geographic distribution of these genotypes is dynamic. In Taiwan, a novel genotype (genotype IV) was identified, which appears to have arisen from an inter-genotypic recombination event between genotype II and III viruses [21]. This is a critical finding, as recombination is a powerful driver of viral evolution, potentially generating strains with altered virulence or antigenic profiles. The presence of vaccine-like strains (similar to 26P4 or Del-Ros) in some Taiwanese field samples also raises concerns about vaccine safety or reversion to virulence [21]. In Africa, the picture is equally diverse. Nigerian isolates from village chickens in Maiduguri showed significant genetic variability, with some isolates clustering with strains from Asia, America, and Europe, while others formed distinct sub-clades or separate clades with as little as 52% homology to the main cluster [1]. This suggests the co-circulation of multiple, highly divergent lineages within a single geographic region. Further characterization of Nigerian CIAV from co-infection studies identified both genotype II and genotype III strains, clustering with isolates from Cameroon and China [2].

The genetic variability is not confined to VP1. While VP2 and VP3 are generally considered more conserved, amino acid substitutions have been documented in all three viral proteins in Chinese isolates [5]. The functional significance of these substitutions, particularly in VP1, is linked to pathogenicity. For instance, the Korean study demonstrated that isolates from three major genotypes (IIb, IIIa, IIIb) all caused anaemia, severe growth retardation, and immunosuppression in one-day-old SPF chicks, but one isolate (17AD008, genotype IIIb) exhibited higher pathogenicity in vivo and superior cellular adaptability in vitro [10]. This suggests that specific genetic signatures within these genotypes can modulate virulence. The increasing genetic variability, driven by both mutation and recombination, is a major research gap. As noted in a recent review, these changes could lead to immune escape from existing vaccine-induced immunity and alter the transmission and virulence patterns of the virus in the future [11]. Continuous molecular surveillance, as recommended by the World Organisation for Animal Health (WOAH) for economically significant pathogens, is therefore essential to track the emergence of new variants and inform the design of next-generation diagnostics and vaccines.

Epidemiology and Global Prevalence of Chicken Infectious Anaemia Virus

Chicken infectious anaemia virus (CIAV) represents one of the most ubiquitous and economically consequential immunosuppressive pathogens confronting the global poultry industry. Since its initial isolation by Yuasa and colleagues in Japan in 1979 during investigations of Marek’s disease outbreaks [18], the virus has been recognized as a near-ubiquitous contaminant of commercial and village poultry operations worldwide. The epidemiology of CIAV is characterized by its extraordinary environmental resistance, its capacity for both horizontal and vertical transmission, and its ability to establish persistent infections that predispose flocks to a cascade of secondary viral and bacterial pathogens. Understanding the global prevalence patterns, regional genotypic distributions, and ecological drivers of CIAV transmission is essential for designing effective control strategies and mitigating the substantial economic losses attributable to this pathogen.

Global Distribution and Continental Prevalence Patterns

CIAV has been documented on every continent where commercial poultry production exists, with seroprevalence rates frequently exceeding 60% in unvaccinated populations. The virus demonstrates a remarkable capacity to circulate within both intensively managed commercial operations and free-ranging village poultry systems, though the epidemiological dynamics differ substantially between these production contexts.

In the African continent, Nigeria has emerged as a focal point for CIAV epidemiological research, with multiple studies documenting widespread viral circulation. Shettima et al. (2025) reported a molecular prevalence of 42% (42/100) among apparently healthy village chickens in Maiduguri, northeastern Nigeria, using conventional PCR targeting pooled thymus, liver, bursa of Fabricius, and spleen tissues [1]. This finding is particularly significant because it demonstrates that clinically healthy birds can serve as reservoirs for viral shedding, perpetuating environmental contamination. The seroprevalence data from the same region are even more striking: Markus et al. (2024) documented an overall seroprevalence of 68.2% (120/176) among chickens sampled from live bird markets in Jos, Plateau State, with significant spatial heterogeneity between Jos North (51.7%) and Jos South (84.3%) [3]. This regional variation underscores the importance of localized epidemiological factors, including stocking density, biosecurity practices, and climatic conditions, in modulating transmission dynamics. The seroprevalence of concurrent CIAV and infectious bursal disease virus (IBDV) infections in Maiduguri was reported at 32.7% (309/944) across multiple avian species, with broilers exhibiting the highest co-infection rate at 46% (144/313) [24]. This finding aligns with the broader understanding that CIAV-induced immunosuppression predisposes birds to secondary infections, creating a syndemic interaction that amplifies disease burden.

The epidemiological landscape in Asia reveals similarly high prevalence rates, though with notable genotypic diversity. In China, the world’s largest poultry producer, Sun et al. (2022) conducted a comprehensive molecular survey across 197 broiler farms in 17 provinces during 2020–2021, detecting CIAV in 65.4% (375/573) of clinical samples by real-time PCR [5]. Regional variation was pronounced, ranging from 46.67% in North China to 81.25% in Central China, suggesting that environmental and management factors significantly influence transmission efficiency. Phylogenetic analysis of 91 VP1 gene sequences revealed that circulating Chinese strains belong to three genotypes (II, IIIa, and IIIb), with genotype IIIa predominating [5]. This genotypic shift has implications for vaccine efficacy, as existing vaccines may not provide optimal protection against emerging lineages. Earlier molecular epidemiological work by Yao et al. (2019) examining sick chickens in China from 2014 to 2015 reported a lower positive rate of 13.30%, with mixed infections accounting for 55.56% of positive cases [19]. The discrepancy between these two Chinese studies likely reflects differences in sampling strategy, the earlier study focused on clinically ill birds, while the later survey included subclinically infected flocks, and highlights the importance of surveillance design in accurately estimating prevalence.

In Vietnam, Huynh et al. (2020) documented CIAV in 73.4% (47/64) of farms and 62.2% (74/119) of individual samples across all 10 investigated provinces in northern Vietnam [6]. Notably, housing system was significantly associated with detection rates (P = 0.003), with free-range systems potentially facilitating environmental exposure. The Vietnamese isolates were classified into genogroups G2 and G3, and critically, none possessed attenuation-associated substitutions, confirming that field strains, not vaccine-derived viruses, were responsible for the observed infections [6]. This distinction is epidemiologically important because it indicates active viral circulation rather than residual vaccine detection.

The Indian subcontinent presents a complex epidemiological picture. Brar et al. (2020) reported a 26.9% (7/26) flock-level prevalence in Haryana using VP2 gene-based PCR, with 11 field strains showing 99.2–100% nucleotide similarity to other Indian isolates [9]. In Kerala, Vidya et al. (2023) detected CIAV antibodies in 87% (80/92) of serum samples by indirect ELISA, while PCR confirmed active infection in 29% (29/100) of suspected cases [17]. The disparity between seroprevalence and molecular detection rates is expected, as antibodies persist long after viral clearance, whereas PCR detects current or recent infection. Krishan et al. (2015) conducted molecular surveillance across North India and Nepal, detecting CIAV genome in 51.4% (95/185) of tissue samples, with concurrent infections including IBD, inclusion body hepatitis, and Marek’s disease [16]. This study demonstrated that CIAV-positive flocks exhibited significant declines in erythrocytic and leukocytic counts, confirming the hematological impact of infection even in subclinical cases.

In East Asia, Taiwan’s CIAV epidemiology is particularly instructive due to the coexistence of vaccination programs and field virus circulation. Ou et al. (2018) detected CIAV DNA in 52.6% (72/137) of flocks sampled between 2010 and 2015, with phylogenetic analysis revealing a novel genotype IV in addition to genotypes II and III [21]. Critically, five Taiwanese isolates showed high similarity to vaccine strains 26P4 and Del-Ros, suggesting that vaccine-derived viruses may revert to virulence or contribute to genetic diversity through recombination. Indeed, one Taiwanese isolate in genotype IV appeared to result from inter-genotypic recombination between genotypes II and III [21]. This finding has profound implications for vaccine safety and highlights the need for regular genetic monitoring of circulating strains.

Korea’s CIAV landscape, as characterized by Song et al. (2024), revealed that 28 complete genome sequences from Korean isolates clustered into four groups: IIa (7.1%), IIb (32.1%), IIIa (28.6%), and IIIb (32.1%), with no strains clustering with the available Korean vaccine strain [10]. The predominance of genotypes IIb and IIIb in Korea contrasts with the IIIa predominance in China, suggesting geographically distinct evolutionary trajectories. Importantly, experimental infection of one-day-old SPF chicks with representative strains from each major genotype (IIb, IIIa, and IIIb) demonstrated that all genotypes induced anemia, severe growth retardation, and immunosuppression, though the IIIb strain (17AD008) exhibited the highest pathogenicity [10]. This genotype-specific pathogenicity underscores the importance of molecular surveillance for predicting disease severity in field outbreaks.

Prevalence in Village and Backyard Poultry Systems

The epidemiology of CIAV in village and backyard poultry systems deserves particular attention, as these production systems often serve as reservoirs for viral persistence and sources of infection for commercial operations. In Sri Lanka, Hassim et al. (2025) reported a striking 87.50% seroprevalence of CIAV among village chickens in the Central Province, with semi-intensive rearing systems predominating (75%) and only 18.75% of farmers vaccinating their flocks [4]. Seroprevalence was significantly associated with flock size (P = 0.04) and veterinary consultation (P = 0.05), indicating that management practices directly influence infection risk. The high prevalence in village systems likely reflects the combination of limited biosecurity, multi-age flock structures, and environmental contamination with resistant virus particles.

In Nigeria, the seroprevalence of concurrent CIAV and IBDV antibodies was 29.9% (120/401) in village chickens, compared to 46% (144/313) in broilers [24]. The lower co-infection rate in village chickens may reflect reduced exposure to the high-density conditions that facilitate IBDV transmission, though CIAV alone remains highly prevalent. The molecular characterization by Shettima et al. (2025) revealed that Nigerian CIAV isolates from village chickens formed clusters with isolates from India, Thailand, Japan, Taiwan, China, USA, and Australia, while two isolates (CIAV 14 and CIAV 36) diverged to form a distinct sub-clade, and two others (CIAV 79 and CIAV 39) formed a separate clade with only 52–57% homology to the main cluster [1]. This genetic diversity suggests multiple introductions of CIAV into Nigerian village poultry populations, possibly through international trade in poultry products or migratory birds.

Co-infection Dynamics and Epidemiological Synergy

One of the most epidemiologically significant features of CIAV is its capacity to synergize with other pathogens, creating complex disease syndromes that are more severe than the sum of their parts. The immunosuppressive nature of CIAV, mediated through depletion of CD4+ and CD8+ T lymphocytes, downregulation of cytokine expression, and induction of apoptosis in thymocytes and hematopoietic precursor cells, creates a permissive environment for secondary infections [13, 15, 28].

In Nigeria, Adedeji et al. (2024) documented co-infections of Marek’s disease virus (MDV) and CIAV in 45.8% (11/24) of tumorous tissue samples from suspected MD cases, with 100% of broiler samples and 27.7% of layer/pullet samples showing co-infection [2]. Phylogenetic analysis revealed that Nigerian CIAV sequences belonged to genotypes II and III, clustering with isolates from Cameroon and China, while MDV sequences clustered with very virulent MDV from Egypt and Italy [2]. The high co-infection rate in broilers likely reflects the early age at which broilers are exposed to both pathogens, combined with the immunosuppressive effects of CIAV that impair vaccine-induced immunity against MDV.

In Trinidad and Tobago, Jordan et al. (2019) investigated mortality rates of up to 75% in commercial broiler flocks and identified co-infection with CIAV and fowl adenovirus (FAdV) in clinically affected birds from eight farms, while all samples tested negative for IBDV [7]. Phylogenetic analysis of seven FAdV strains revealed four circulating serotypes (8a, 8b, 9, and 11), suggesting that CIAV-induced immunosuppression may facilitate the emergence of multiple FAdV serotypes simultaneously [7]. This finding has practical implications for vaccine development, as serotype-specific FAdV vaccines may be necessary in regions where CIAV is endemic.

In India, Suohu et al. (2024) investigated 60 layer flocks aged 6–55 weeks with histories suggestive of CIAV and concurrent infections, finding that 46 flocks were CIAV-positive, of which 17 had concurrent infections [25]. Among these, six flocks showed co-infection with MDV, while 11 flocks exhibited gangrenous dermatitis involving Clostridium perfringens, Staphylococcus aureus, and Escherichia coli. The pathological changes in co-infected birds were more severe than in CIAV-only infections, with pleomorphic lymphocyte infiltration and fibrinous exudate in CIAV-MDV co-infections, and bacterial clusters indicating septicemia in CIAV-gangrenous dermatitis cases [25]. This study demonstrates that CIAV acts as a gateway pathogen, enabling opportunistic bacteria to cause systemic disease.

The interaction between CIAV and respiratory viruses has been experimentally characterized by Erfan et al. (2019), who demonstrated that pre-infection with CIAV significantly enhanced and prolonged subsequent infections with low pathogenic avian influenza H9N2 and infectious bronchitis virus in SPF chickens [26]. CIAV-pre-infected birds produced considerably higher viral titers in oropharyngeal swabs, tracheas, and kidneys, and developed clinical signs that were absent in birds infected with respiratory viruses alone. The immunological mechanism involved elevated levels of IL-6 and IFN-γ, suggesting that CIAV dysregulates the cytokine response to respiratory pathogens [26]. From an epidemiological perspective, this finding implies that CIAV-endemic regions may experience more severe and prolonged outbreaks of respiratory diseases, complicating control efforts.

Vertical Transmission and Breeder Flock Epidemiology

The epidemiology of CIAV is profoundly influenced by its capacity for vertical transmission through the embryonated egg, which allows the virus to bypass biosecurity measures and infect progeny before maternal antibody wanes. Rodrigues et al. (2022) evaluated the rate of maternal antibody transfer from broiler breeders vaccinated at 14 weeks of age to their progeny under field conditions, analyzing 92 sera samples from 93,000 breeders and 366 progeny samples [22]. Breeder antibody titers ranged from 5,051 to 8,660 by ELISA, with an average transfer rate of 63% to progeny. Maternal antibodies lasted up to the second week of life, providing a critical window of protection [22]. However, the waning of maternal antibodies by 14–21 days of age coincides with the period of highest susceptibility to clinical CIA, creating a vulnerable window during which chicks are susceptible to both vertical and horizontal infection.

The dynamics of CIAV infection in SPF flocks, which must remain CIAV-free for vaccine production and diagnostics, have been studied by Vagnozzi et al. (2018), who demonstrated that seroconversion occurred at 14 days post-inoculation (DPI) in vaccinated broiler breeder pullets, while CIAV genome was detectable by qPCR at 7 DPI in both invasive and non-invasive samples [29]. Notably, only invasive samples (thymus, spleen, bone marrow) remained qPCR-positive at 21 DPI despite seroconversion, indicating that serological monitoring alone may underestimate the true prevalence of infection in breeder flocks [29]. This finding has critical implications for SPF flock certification programs and highlights the need for molecular surveillance in addition to serology.

Genotypic Diversity and Global Phylogenetic Patterns

The global epidemiology of CIAV is characterized by substantial genetic diversity, with multiple genotypes circulating simultaneously within geographic regions and evidence of inter-genotypic recombination. The classification system for CIAV genotypes has evolved as sequencing data have accumulated. Sun et al. (2022) identified three genotypes (II, IIIa, and IIIb) among Chinese isolates, with IIIa predominating [5]. Song et al. (2024) refined this classification for Korean isolates, identifying four groups (IIa, IIb, IIIa, IIIb) [10]. Ou et al. (2018) proposed a novel genotype IV for Taiwanese isolates, some of which appeared to be recombinants between genotypes II and III [21]. The existence of recombinant strains suggests that co-infection with multiple genotypes occurs in the field, providing opportunities for genetic exchange that may generate variants with altered pathogenicity or antigenicity.

The VP1 gene, which encodes the major capsid protein and contains the neutralizing epitopes, is the primary target for phylogenetic analysis. Yao et al. (2019) demonstrated that VP1 sequences from 15 new Chinese strains formed four distinct groups (A–D), with VP1 diversity indicating virulence potential, while VP2 and VP3 remained highly conserved [19]. The conservation of VP2 and VP3 across genotypes suggests that these proteins are under strong functional constraint, whereas VP1 is subject to immune selection pressure. This has implications for vaccine design, as VP1-based vaccines may need to be updated periodically to match circulating genotypes.

Karki et al. (2024) emphasized in their updated review that emerging genotypes and recombination events in the CIAV genome have been reported from multiple countries, and the increasing genetic variability may lead to immune escape and altered transmission patterns [11]. The spectrum of genotypic variation suggests the need for detailed genetic studies of currently circulating CIAV genotypes and the design of updated diagnostics and vaccines [11]. This is particularly relevant given that all CIAV strains identified to date belong to the same serotype, meaning that antigenic differences are minimal despite genetic diversity [14]. However, the relationship between genotype and pathogenicity remains incompletely understood, and phenotypic characterization of new genotypes is urgently needed.

Risk Factors and Spatial Heterogeneity

The epidemiological literature consistently identifies several risk factors associated with CIAV prevalence. Age is a critical determinant, with young chickens (2–4 weeks) being most susceptible to clinical disease, while older birds typically experience subclinical infections [11]. However, even subclinical infections in older birds result in immunosuppression, as demonstrated by Wani et al. (2015), who showed that CIAV infection at 6 weeks of age caused significant declines in CD4+ and CD8+ T cell populations in both spleen and blood at 15 DPI, despite the absence of clinical signs [13].

Housing system and management practices significantly influence prevalence. Huynh et al. (2020) found that housing system was significantly associated with CIAV detection rates in Vietnam (P = 0.003) [6]. In Sri Lanka, semi-intensive rearing was associated with high seroprevalence (87.50%), likely due to environmental contamination and multi-age flock structures [4]. Flock size was also significantly associated with seroprevalence in Sri Lankan village chickens (P = 0.04) [4], consistent with the density-dependent transmission dynamics expected for a horizontally transmitted pathogen.

Spatial heterogeneity in prevalence, as documented by Markus et al. (2024) between Jos North (51.7%) and Jos South (84.3%) in Nigeria [3], and by Sun et al. (2022) across Chinese provinces (46.67% to 81.25%) [5], suggests that local factors, including climate, biosecurity practices, and poultry density, modulate transmission efficiency. The mechanisms underlying this spatial variation warrant further investigation, as they may identify modifiable risk factors for targeted interventions.

Economic and Public Health Implications

While CIAV is not zoonotic and poses no direct threat to human health, its economic impact on the poultry industry is substantial and indirect effects on food security are significant. The World Organisation for Animal Health (WOAH) recognizes CIAV as an important pathogen of poultry, though it is not listed as a notifiable disease. The economic losses attributable to CIAV stem from increased mortality, reduced growth rates, vaccination failures, and increased susceptibility to secondary infections that require antimicrobial treatment. The latter is particularly concerning in the context of antimicrobial resistance, as CIAV-induced immunosuppression may drive increased antibiotic use in poultry production.

The Food and Agriculture Organization (FAO) has emphasized the importance of controlling immunosuppressive diseases in poultry to improve food security and rural livelihoods, particularly in

Diagnostics and Detection Methods for Chicken Infectious Anaemia Virus

The accurate and timely diagnosis of Chicken Infectious Anaemia Virus (CIAV) is a cornerstone of effective poultry health management, given the virus's ubiquitous nature, its profound immunosuppressive capabilities, and its propensity to exacerbate the pathogenicity of concurrent infections [11, 18, 25]. The diagnostic landscape for CIAV has evolved significantly from early reliance on clinical observation and histopathology to a sophisticated array of molecular, serological, and immunological tools. Each method offers distinct advantages and limitations, and their strategic deployment is critical for surveillance, outbreak investigation, vaccine efficacy assessment, and the maintenance of specific-pathogen-free (SPF) flocks. The World Organisation for Animal Health (WOAH) recognizes the economic importance of CIAV, and standardized diagnostic protocols are essential for international trade and biosecurity. The selection of an appropriate diagnostic approach must consider the infection stage, sample type, flock history, and the specific objective, whether it be detecting active viral replication, confirming prior exposure, or characterizing circulating viral strains for epidemiological and vaccine-matching purposes.

Molecular Detection Methods: The Gold Standard for Active Infection

The detection of CIAV genomic material has become the primary approach for confirming active infection, particularly in subclinical cases where serology may be inconclusive. Among these, the polymerase chain reaction (PCR) , in its various formats, remains the most widely employed and validated technique.

Conventional PCR, targeting specific genes such as VP1 or VP2, has been instrumental in establishing the global prevalence of CIAV. Studies have consistently demonstrated its efficacy across diverse poultry populations and sample types. For instance, Shettima et al. [1] used conventional PCR to detect a 42% prevalence of CIAV in pooled tissue samples (thymus, liver, bursa, spleen) from apparently healthy village chickens in Nigeria, highlighting the virus's endemic nature even in the absence of clinical signs. Similarly, in northern Vietnam, Huynh et al. [6] reported a 62.2% detection rate in individual samples and a 73.4% farm-level prevalence using PCR, confirming the widespread distribution of the virus. The assay's robustness is further underscored by its utility in detecting co-infections, a critical aspect of CIAV pathogenesis. Adedeji et al. [2] employed PCR targeting the VP1 gene to reveal a 45.8% co-infection rate of CIAV with Marek's disease virus (MDV) in Nigerian poultry flocks, a finding that has significant implications for vaccination failures and disease severity. The technique's specificity is well-documented, with no cross-reactivity observed against other common avian viruses when using well-designed primers [23]. In the Indian subcontinent, PCR-based surveys have confirmed the virus's presence in multiple states, with Brar et al. [9] reporting a 26.9% flock-level positivity in Haryana and Vidya et al. [17] finding 29% of suspected cases positive in Kerala.

Real-time quantitative PCR (qPCR) offers substantial advantages over conventional PCR by providing both qualitative detection and quantitative viral load data. This is particularly valuable for understanding viral dynamics, pathogenicity, and the effectiveness of control measures. Vagnozzi et al. [29] demonstrated the superior sensitivity of qPCR for early detection, detecting CIAV DNA in invasive (thymus, spleen) and non-invasive (feather shafts, cloacal swabs) samples as early as 7 days post-inoculation (DPI), preceding seroconversion which occurred at 14 DPI. This early detection window is crucial for rapidly identifying infected birds and implementing containment protocols, especially in SPF flocks where CIAV contamination is economically devastating. The quantitative capacity of qPCR is powerfully illustrated by Wani et al. [28], who developed a standard curve using a recombinant plasmid (VP2-pET32b) to precisely measure viral load in various tissues of subclinically infected chicks. Their work revealed that peak viral load occurs between 10-20 DPI, with the highest concentrations found in blood, followed by the thymus, providing critical insights into viral tropism and pathogenesis. Large-scale epidemiological studies, such as the comprehensive survey by Sun et al. [5] in China, which screened 573 samples from 197 farms using real-time PCR, reported a 65.4% positivity rate, demonstrating the scalability of this method for national surveillance programs. The high sensitivity of qPCR also makes it indispensable for vaccine development, as Chellappa et al. [8] utilized real-time PCR to measure cytokine gene expression (IFN-γ, IL-4) to evaluate the cell-mediated immune response induced by a novel bivalent NDV-CIAV vaccine.

Isothermal amplification techniques, such as loop-mediated isothermal amplification (LAMP) , represent a significant advancement for field-deployable diagnostics. The multiplex fluorescence-based LAMP (mLAMP) assay developed by Fan et al. [23] is a landmark innovation, allowing for the simultaneous detection of CIAV, chicken parvovirus (ChPV), and fowl aviadenovirus serotype 4 (FAdV-4) in a single reaction. Targeting the conserved VP1 gene of CIAV, this assay demonstrated exceptional analytical sensitivity, with a detection limit of 749 copies of the recombinant plasmid, and 100% concordance with conventional PCR when tested on field samples. The ability to differentiate between these three viruses based on distinct fluorescence signals, visible to the naked eye, is a transformative advantage for laboratories in rural or resource-limited settings. This method bypasses the need for costly thermocyclers, relying instead on a simple water bath or heat block, dramatically reducing the barrier to rapid, on-farm diagnosis.

The choice of target gene for molecular detection is critical. While VP1 is the most variable and responsible for antigenic diversity and virulence, making it ideal for phylogenetic and epidemiological studies, the VP2 gene is highly conserved and is often the preferred target for broad-based screening assays [9, 16, 17]. The NS gene is a common target for ChPV, but for CIAV, the VP1 and VP2 loci remain the standards [15, 23]. Sequencing and phylogenetic analysis of these amplicons, particularly the VP1 gene, is indispensable for molecular epidemiology. This approach has revealed the coexistence of multiple genotypes globally, with studies in China showing a predominance of genotype IIIa [5], while Korean isolates were distributed across groups IIa, IIb, IIIa, and IIIb [10]. Critically, sequencing can differentiate between field strains and vaccine-derived viruses, a necessity for interpreting positive results in vaccinated flocks. Huynh et al. [6] used phylogenetic analysis to confirm that all Vietnamese isolates clustered in genogroups G2 and G3 and lacked attenuating substitutions, proving they were not vaccine-like. Similarly, Ou et al. [21] used sequencing to identify both recombination events and highly similar sequences to vaccine strains (26P4 and Del-Ros) in Taiwan, highlighting the risk of vaccine strain reversion or persistence in the field. Advanced molecular characterization, such as PCR-RFLP (restriction fragment length polymorphism) analysis of the full viral genome using enzymes like Hind III, Pst I, Nhe I, and Mbo II, provides a rapid method for genotyping and has been used to compare Indian isolates, revealing indistinguishable patterns among some field strains [16].

Serological Surveillance: Monitoring Exposure and Immunity

Serological methods are essential for understanding population-level exposure, monitoring vaccine-induced immunity, and assessing maternal antibody transfer. Enzyme-linked immunosorbent assay (ELISA) is the dominant serological tool due to its high throughput, objectivity, and quantitative output. Indirect ELISA, which detects anti-CIAV antibodies in serum, is widely used for prevalence studies. The studies from Nigeria by Markus et al. [3] reported an overall seroprevalence of 68.2% in chickens from Jos, with significant spatial variation (51.7% in Jos North vs. 84.3% in Jos South), illustrating the power of ELISA for geographic risk mapping. In Sri Lanka, Hassim et al. [4] found a remarkably high seroprevalence of 87.5% in village chickens, strongly associated with flock size and veterinary consultation practices. Shettima et al. [24] used ELISA to detect concurrent antibodies to CIAV and infectious bursal disease virus (IBDV) in a large-scale survey of 944 poultry sera, reporting a 32.7% co-seropositivity rate with significant variation across species (46% in broilers vs. 3.4% in ducks).

ELISA is also the standard method for evaluating vaccine efficacy and maternal immunity. Rodrigues et al. [22] used a commercial ELISA kit to titrate antibodies in broiler breeders vaccinated at 14 weeks, demonstrating that high antibody titers (ranging from 5051 to 8660) were effectively transferred to progeny at an average rate of 63%, providing protection up to the second week of life. This data is crucial for refining vaccination schedules. Furthermore, Chellappa et al. [8] used a CIAV-specific ELISA to quantify humoral responses to a novel bivalent vaccine, showing a significant difference in antibody titers between vaccinated and control groups, with titers maintained until 84 days of age after a booster. The sensitivity of ELISA for detecting prior exposure is high, as demonstrated by Vidya et al. [17] in Kerala, where 80 out of 92 serum samples (87%) were positive by indirect ELISA, a much higher rate than the 29% PCR positivity, indicating that most birds had been exposed but were not actively viremic at the time of sampling.

Despite its utility, serology has limitations. It cannot distinguish between antibodies derived from natural infection, vaccination, or maternal transfer. It also has a lag phase; as Vagnozzi et al. [29] showed, seroconversion occurs at 14 DPI, while molecular detection can identify infection a week earlier. Therefore, serology is most valuable for surveillance and monitoring, rather than for diagnosing acute clinical cases.

Advanced and Integrative Diagnostic Approaches

Beyond molecular and serological methods, a comprehensive diagnostic workup often integrates histopathology, immunohistochemistry (IHC) , flow cytometry, and clinical pathology. Histopathological examination provides direct evidence of CIAV-induced lesions. The hallmark findings include severe lymphoid depletion in the thymic cortex, aplastic bone marrow with depletion of hematopoietic cells, and the presence of characteristic intranuclear acidophilic inclusion bodies in thymocytes and erythroid precursors [20, 25]. Suohu et al. [25] documented that concurrent infections (e.g., CIAV with Marek's disease or gangrenous dermatitis) produced more intense pathological changes, such as pleomorphic lymphocyte infiltration and fibrinous exudate, compared to CIAV infection alone. Castaño et al. [20] utilized IHC targeting the VP1 and VP3 proteins to elucidate tissue tropism in naturally infected broilers, demonstrating that the thymus and bone marrow are the primary target organs. Their work further revealed that CD3+ T lymphocytes may be key vectors for viral dissemination from these primary sites to peripheral organs, and that VP3-mediated apoptosis, confirmed by caspase-3 co-localization, was the primary mechanism of cell death in the thymus. Flow cytometry offers a highly sensitive method for quantifying the immunosuppressive effects of CIAV. Wani et al. [13] demonstrated a significant decrease in both CD4+ and CD8+ T cell populations in the spleen and blood of subclinically infected chicks at 15 DPI, directly correlating with reduced hematocrit and total leukocyte counts. This immunological profiling is critical for understanding the long-term consequences of infection beyond the acute phase.

Hematological analysis remains a valuable, low-cost screening tool. Measuring packed cell volume (PCV) or hematocrit is a classic indicator of the anemia central to CIA pathogenesis. Significant declines in PCV, total leukocyte count (TLC), and peripheral lymphocyte count (PLC) are consistent findings in infected birds [8, 13, 16, 25, 30]. The study by Erfan et al. [26] used clinical scoring and viral shedding dynamics via qPCR to demonstrate that pre-infection with CIAV enhances and prolongs subsequent infections with avian influenza (H9N2) and infectious bronchitis virus, underscoring the utility of hematological parameters in tracking secondary complications. Finally, direct virus isolation in cell culture (e.g., MSB1 cells), though labor-intensive and time-consuming, remains the definitive reference method for obtaining live virus for full characterization, vaccine development, and challenge studies. This method, combined with Western blotting and indirect immunofluorescence assays (IFA) , was crucial for the isolation and confirmation of 15 new CAV strains in China by Yao et al. [19], allowing for subsequent whole-genome sequencing and virulence assessment.

Co-infections and Immunosuppressive Interactions with Marek's Disease Virus

The interplay between Chicken Infectious Anaemia Virus (CIAV) and Marek's Disease Virus (MDV) represents one of the most clinically and economically consequential interactions in modern poultry virology. This co-infection paradigm is particularly insidious because both pathogens independently target the avian immune system, CIAV through the depletion of thymic and haematopoietic progenitor cells, and MDV through the induction of T-cell lymphomas and profound immunosuppression, yet their combined effect is far more devastating than the sum of their individual pathogenicities. Understanding this synergistic relationship is critical for interpreting vaccination failures, disease outbreaks in vaccinated flocks, and the emergence of very virulent MDV strains globally.

Epidemiological Evidence of Widespread Co-Infection

The epidemiological landscape of MDV-CIAV co-infection has been revealed through increasingly sophisticated molecular surveillance, particularly in regions where poultry production intensifies without comprehensive biosecurity. A landmark investigation in Nigeria demonstrated that among tumourous tissue samples from suspected Marek's disease cases, co-infections of MDV and CIAV were detected in 45.8% of samples, with all broiler samples (100%) showing concurrent infection compared to 27.7% of layer/pullet samples [2]. This stark disparity between production types likely reflects the higher stocking densities, greater environmental contamination, and more intensive stress factors characteristic of broiler operations, all of which potentiate both viral replication and immunosuppression. The Nigerian MDV isolates clustered with very virulent strains from Egypt and Italy, while the accompanying CIAV isolates belonged to genotypes II and III, clustering with Cameroonian and Chinese strains [2], suggesting that co-circulation of diverse CIAV genotypes may drive the evolution of MDV virulence.

Further evidence from India reinforces the pervasiveness of this interaction. In layer flocks from Namakkal, Tamil Nadu, 6 out of 46 CIAV-positive flocks (13.0%) exhibited concurrent MDV infection, with these co-infected flocks demonstrating markedly more severe pathological changes, including severe organ enlargement and nodular lesions, compared to flocks infected with CIAV alone [25]. Similarly, a molecular epidemiological survey across North India and Nepal detected MDV in conjunction with CIAV in multiple commercial flocks, with PCR-RFLP analysis revealing indistinguishable restriction patterns among co-circulating CIAV isolates [16], suggesting a common source or stable viral population under selective pressure from MDV co-infection. The Chinese experience mirrors these findings; during 2014–2015, mixed infections accounted for 55.56% of all CAV-positive cases in sick chickens, with MDV being among the most frequently detected co-pathogens [19].

Mechanistic Synergy: Amplified Apoptosis and Lymphoid Depletion

At the cellular level, the MDV-CIAV interaction is characterized by a catastrophic acceleration of programmed cell death in the thymus, the central organ for T-cell development and immune competence. Experimental co-infection studies in specific-pathogen-free (SPF) chicks have provided definitive mechanistic insights. When chicks were challenged with CIAV on day 1 and very virulent MDV on day 14, the levels of caspase-3, the key executioner protease in the apoptotic cascade, were significantly elevated compared to either single infection group from day 14 post-infection onwards [12]. Critically, while the CIAV-only group showed declining caspase-3 levels by day 42, the co-infected group maintained significantly higher levels throughout the study period [12], indicating that MDV co-infection prevents the normal resolution of CIAV-induced apoptosis. This sustained apoptotic pressure leads to profound and irreversible thymic atrophy, effectively dismantling the adaptive immune response before it can be mounted.

The molecular basis for this synergy involves the unique properties of CIAV's apoptin (VP3) protein, which selectively induces apoptosis in thymocytes and erythrocyte precursors [18]. MDV, through its meq oncogene, dysregulates cellular survival pathways, creating a cellular environment where apoptin's pro-apoptotic activity is amplified. The resulting thymic destruction is compounded by the fact that both viruses target overlapping cell populations: CIAV infects haemopoietic progenitor cells and CD3+ T lymphocytes in the thymic cortex and bone marrow [20], while MDV transforms activated CD4+ T cells. The consequence is a dual assault on both the developing T-cell repertoire and the mature effector population, manifesting as severe depletion of both CD4+ and CD8+ T-cell subsets in the spleen and blood [13]. Flow cytometric analyses have demonstrated that subclinical CIAV infection alone can decrease these populations significantly by 15 days post-infection [13]; when MDV co-infection is superimposed, the reduction is even more pronounced, leaving birds functionally athymic.

Immunological Consequences: Vaccination Failure and Secondary Infections

The immunosuppressive synergy between CIAV and MDV has profound translational implications, particularly for vaccination programmes. Marek's disease is currently controlled through widespread vaccination with serotype 1 (CVI988/Rispens), serotype 2 (SB-1), or serotype 3 (HVT) vaccines. However, the immunosuppression induced by CIAV can render these vaccines ineffective by compromising the very immune mechanisms, particularly cell-mediated immunity, required for vaccine-induced protection. In broiler flocks where MD vaccination failures were documented, co-infection with CIAV was detected in 100% of cases [2], a finding that strongly implicates CIAV as a critical factor in breakthrough MD infections. This is consistent with the broader principle that immunosuppressive agents, including CIAV, are major contributors to vaccine failures in poultry [11, 14].

Furthermore, the MDV-CIAV co-infected bird becomes a "superspreader" for other pathogens. The profound lymphopenia and impaired cytokine responses, including downregulation of IL-1β, IL-10, IL-12β, and GM-CSF [15], create an immunological vacuum that opportunistic bacteria and viruses readily exploit. In layer flocks co-infected with CIAV and MDV, the pathological picture is dominated not just by lymphomas but by severe gangrenous dermatitis caused by Clostridium perfringens, Staphylococcus aureus, and Escherichia coli [25]. These bacterial infections, rarely pathogenic in immunocompetent birds, cause septicemia and death when superimposed on CIAV-MDV co-infection. The intranuclear inclusion bodies characteristic of CIAV infection in thymic and bone marrow cells [20] are observed alongside pleomorphic lymphocyte infiltrations typical of MDV lymphomas [25], creating a histopathological picture that is both diagnostically challenging and clinically catastrophic.

Transmission Dynamics and Evolutionary Implications

The co-infection dynamics are further complicated by the contrasting transmission routes of these two viruses. CIAV can be transmitted both vertically (through the egg from viraemic breeders) and horizontally (through faecal-oral and respiratory routes) [11, 14], whereas MDV is transmitted exclusively horizontally through cell-associated virus in feather dander and dust. However, the immunosuppression induced by CIAV may enhance MDV replication and shedding, increasing the environmental viral load and thus the transmission efficiency of MDV within a flock. This creates a positive feedback loop: CIAV infection increases MDV transmission, leading to higher MDV challenge doses, which in turn cause more severe immunosuppression and greater susceptibility to CIAV. The presence of vaccine-like CIAV strains in Taiwan that nonetheless induce clinical disease [21] suggests that co-infection with MDV may also overcome the attenuation of CIAV vaccines, effectively converting a vaccine virus into a pathogenic one through immunological synergism.

The genetic diversity of CIAV circulating in MDV-co-infected flocks is also notable. In Nigeria, CIAV isolates from co-infected birds formed a distinct sub-clade with only 52–57% homology to other Nigerian isolates [1], suggesting that MDV co-infection may select for specific CIAV genotypes or that these genotypes are particularly adept at exploiting the MDV-induced immunocompromised state. Similarly, the predominant CIAV genotype IIIa in China [5] and genotypes IIb, IIIa, and IIIb in Korea [10] have been identified in flocks with concurrent MDV infections, indicating that no single CIAV genotype is exclusively associated with MDV co-infection. However, the observation that Vietnamese CIAV isolates lack attenuation-associated substitutions and belong to genogroups G2 and G3 [6] suggests that field strains circulating in regions with high MDV prevalence may be inherently more pathogenic.

Implications for Disease Control and Biosecurity

The recognition that MDV-CIAV co-infection is not merely an academic curiosity but a primary driver of disease in vaccinated flocks has significant practical implications. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) have both identified immunosuppressive agents as major threats to global poultry production, emphasizing the need for integrated control strategies. The high seroprevalence of CIAV, 68.2% in Nigerian poultry [3], 87.5% in Sri Lankan village chickens [4], and 65.4% in Chinese broiler farms [5], underscores the ubiquity of this pathogen and the near-inevitability of its interaction with MDV in field conditions.

Control strategies must therefore move beyond monovalent vaccination approaches. The development of bivalent vaccines, such as the Newcastle disease virus-vectored CIAV vaccine expressing VP1 and VP2 proteins [8], represents a promising avenue, but these must be evaluated for their ability to protect against MDV co-infection. Furthermore, the maintenance of maternal antibodies against CIAV in broiler breeders [22] is critical for protecting progeny during the first two weeks of life, when they are most vulnerable to both CIAV and MDV. However, maternal antibody levels decline by the second week [22], leaving a window of susceptibility that coincides with the period when MDV exposure from the environment is highest. The implementation of strict biosecurity measures, including all-in-all-out production systems, thorough cleaning and disinfection between flocks (recognizing CIAV's exceptional environmental resistance [14]), and systematic monitoring for both CIAV and MDV using multiplex diagnostic tools [23], is essential for breaking the co-infection cycle.

Pathogenesis and Clinical Manifestations of Chicken Infectious Anaemia

The pathogenesis of Chicken Infectious Anaemia Virus (CIAV) represents a paradigm of viral-induced immunosuppression and hematopoietic destruction, orchestrated through a precisely choreographed sequence of cellular tropism, apoptotic induction, and lymphoid depletion. Understanding this intricate pathogenic cascade is fundamental to comprehending the clinical spectrum of disease, which ranges from fulminant anaemia and mortality in the susceptible young chick to subclinical yet profoundly immunosuppressive infections in older birds. The clinical manifestations, therefore, are not merely a direct consequence of viral cytopathology but are inextricably linked to the virus’s capacity to dismantle the host’s immune architecture, thereby predisposing the bird to a plethora of secondary and opportunistic infections.

Viral Tropism and the Initiation of Cellular Destruction

The pathogenic journey of CIAV begins with its remarkable tropism for rapidly dividing precursor cells within the bone marrow and the thymic cortex [11, 20]. Following entry, typically via the oral or respiratory route, the virus disseminates haematogenously to these primary target organs. The bone marrow, the site of haematopoiesis, becomes a primary battlefield. CIAV infects erythroid and myeloid progenitor cells, leading to a profound aplasia of the haematopoietic tissue [20, 21]. This direct cytolytic effect on precursor cells is the root cause of the characteristic anaemia, leukopenia, and thrombocytopenia observed clinically. Concurrently, the thymus, the central organ for T-cell maturation, suffers a devastating assault. The virus exhibits a pronounced predilection for cortical thymocytes, resulting in severe lymphoid depletion and thymic atrophy [20, 25]. This dual attack on both the haematopoietic and lymphoid compartments establishes the foundation for the dual clinical hallmarks of CIA: aplastic anaemia and profound immunosuppression.

The molecular executioner of this cellular destruction is the viral protein VP3, universally known as apoptin [18]. Apoptin is a potent, non-structural protein that uniquely and selectively induces apoptosis in chicken thymocytes and erythrocyte precursors, as well as in various transformed mammalian cell lines [18, 27]. The mechanism is exquisitely targeted; apoptin localizes to the nucleus of these susceptible cells, triggering a caspase-dependent apoptotic cascade. Experimental evidence has demonstrated significantly higher levels of caspase-3 release in CIAV-infected chicks, confirming the central role of apoptin-mediated apoptosis in thymocyte destruction [12]. This process is not merely a passive cell death but an active, programmed dismantling of the immune system’s core components. The peak of thymic DNA fragmentation, indicative of apoptosis, has been observed between 7 and 10 days post-infection (dpi), correlating directly with the nadir of clinical disease and the downregulation of protective cytokine profiles [15].

The Immunosuppressive Cascade: Depletion of T-Cell Populations and Cytokine Dysregulation

The hallmark of CIAV pathogenesis is its ability to induce a state of severe, generalized immunosuppression, which far outlasts the acute phase of anaemia. This is achieved through a multi-pronged attack on the cellular immune system. Flow cytometric analyses have unequivocally demonstrated that CIAV infection leads to a significant and sustained decrease in both CD4+ (T-helper) and CD8+ (cytotoxic T-cell) lymphocyte populations in the spleen and peripheral blood [13]. This depletion of T-cell subsets cripples the adaptive immune response, leaving the bird vulnerable to a wide array of concurrent pathogens and compromising the efficacy of routine vaccinations [16, 25, 30].

The immunosuppression is further compounded by a profound dysregulation of the cytokine network. CIAV infection induces a state of cytokine downregulation, particularly affecting key mediators of cell-mediated immunity. Studies have documented significant downregulation of interleukin (IL)-1β, IL-12β, and granulocyte-macrophage colony-stimulating factor (GM-CSF) in infected chicks [15]. This suppression of pro-inflammatory and immunostimulatory cytokines impairs the recruitment and activation of immune effector cells. Interestingly, the response is not uniformly suppressive. While IL-2, a critical T-cell growth factor, is decreased in splenic tissue, interferon-gamma (IFN-γ) shows a biphasic response, with a two-to-five-fold increase in both blood and spleen that coincides with peak viral load [28]. This IFN-γ surge, while potentially an attempt at antiviral defense, may paradoxically contribute to the immunopathology. The net effect is a severely compromised immune system that is unable to mount an effective response against the primary viral infection or secondary invaders. This immunosuppressive state is the primary driver of the synergistic pathology observed in co-infections, where CIAV acts as a key predisposing factor for diseases caused by other pathogens [18, 26].

Clinical Manifestations: From Acute Anaemia to Subclinical Immunosuppression

The clinical presentation of CIA is highly age-dependent, a direct reflection of the maturation of the chick’s immune system and the presence of maternal antibodies. The classic, fulminant form of the disease is observed in young chicks, typically between 2 and 4 weeks of age, which are vertically infected or exposed horizontally within the first few days of life in the absence of protective maternal immunity [11, 22]. The onset of clinical signs is often sudden. The most prominent feature is severe anaemia, which manifests as pallor of the comb, wattles, and visible mucous membranes. The haematocrit (packed cell volume, PCV) plummets, often falling below 20%, compared to a normal value of 30% or higher [8, 13]. This profound anaemia leads to lethargy, depression, and weakness. A key pathognomonic sign is the development of gangrenous dermatitis, often referred to as "blue wing disease," characterized by dark, necrotic, and moist lesions on the wings, legs, and abdomen [20, 27]. This is not a direct effect of CIAV but a consequence of the severe immunosuppression and thrombocytopenia, which allows opportunistic bacteria, particularly Clostridium perfringens, Staphylococcus aureus, and Escherichia coli, to proliferate and cause necrotizing cellulitis [25]. Subcutaneous hemorrhages and intramuscular hematomas are also common due to thrombocytopenia. Mortality rates in these acute outbreaks can be substantial, ranging from 10% to 60%, with surviving birds often exhibiting severe growth retardation and stunting [10, 25].

In older chickens, particularly those over 4-6 weeks of age, the clinical picture shifts dramatically. These birds are more resistant to the anaemic form of the disease, largely due to a more mature and resilient haematopoietic system. However, they are not immune to infection. The virus replicates in the thymus and bone marrow, causing a subclinical infection characterized by transient lymphoid depletion and a significant, albeit less overt, immunosuppressive state [13, 28]. This subclinical form is arguably of greater economic importance to the global poultry industry, as it is a hidden driver of poor flock performance. These birds appear clinically normal but are immunologically compromised. This leads to increased susceptibility to secondary viral, bacterial, and fungal infections, including those caused by E. coli, respiratory viruses like Infectious Bronchitis Virus (IBV) and Avian Influenza Virus (H9N2), and other immunosuppressive agents like Infectious Bursal Disease Virus (IBDV) and Marek’s Disease Virus (MDV) [16, 24, 26]. Furthermore, subclinical CIAV infection is a major cause of vaccine failure, as the compromised immune system cannot mount an adequate protective response to routine vaccinations against Newcastle Disease, IBD, or other pathogens [25, 30]. The World Organisation for Animal Health (WOAH) recognizes the significant economic impact of CIAV, particularly its role as a predisposing factor for other diseases, which complicates disease control and surveillance programs globally.

Pathological Synergy in Co-Infections

The true pathogenic impact of CIAV is most devastating when it acts in concert with other pathogens. The virus’s ability to induce profound immunosuppression creates a permissive environment for a wide range of co-infecting agents, leading to synergistic pathology that is far more severe than the sum of its parts. Co-infection with CIAV and Marek’s Disease Virus (MDV) is a well-documented and particularly severe combination. Studies have shown that co-infection leads to a significantly higher degree of apoptosis in thymocytes compared to infection with either virus alone, as evidenced by sustained high levels of caspase-3 [12]. This exacerbates the immunosuppression, leading to more severe lymphoid depletion and more aggressive MDV-induced lymphomagenesis [2, 25]. The pathological lesions in co-infected birds are more intense, with severe enlargement of organs and the presence of pleomorphic lymphocyte infiltration and fibrinous exudates [25].

Similarly, CIAV co-infection with Fowl Adenovirus (FAdV) has been implicated in severe outbreaks of Inclusion Body Hepatitis (IBH) and Hydropericardium Syndrome (HPS), with mortality rates reaching up to 75% in commercial broiler flocks [7]. The immunosuppression induced by CIAV allows FAdV to replicate to higher titers, causing more extensive hepatic necrosis. This synergistic interaction has been reported globally, including in Trinidad and Tobago and Nigeria, where co-infections with CIAV and MDV or FAdV are increasingly recognized as a major cause of flock losses [2, 7]. Furthermore, pre-infection with CIAV has been shown to enhance and prolong subsequent infections with respiratory viruses such as Avian Influenza (H9N2) and Infectious Bronchitis Virus (IBV). CIAV-infected chicks shed significantly higher titers of these respiratory viruses and exhibit more severe clinical signs, a phenomenon linked to elevated levels of IL-6 and IFN-γ, which may contribute to immunopathology rather than protection [26]. The presence of CIAV, therefore, acts as a critical risk factor that can transform a mild, subclinical infection with another agent into a severe, economically devastating disease outbreak. This highlights the necessity for comprehensive diagnostic approaches that include CIAV testing when investigating disease outbreaks in poultry, as recommended by leading veterinary health authorities.

Control Strategies and Preventive Measures for Chicken Infectious Anaemia Virus

The global poultry industry faces persistent economic losses from Chicken Infectious Anaemia Virus (CIAV), a highly resilient, non-enveloped circovirus that induces severe immunosuppression and aplastic anaemia in young chickens [11, 14]. Control strategies must address the virus’s extraordinary environmental stability, its capacity for both horizontal and vertical transmission, and its synergistic interactions with other pathogens. An integrated approach combining rigorous biosecurity, strategic vaccination, molecular surveillance, and immunomodulatory support is essential to mitigate the impact of CIAV on flock health and productivity. The World Organisation for Animal Health (WOAH) recognizes CIAV as a significant immunosuppressive agent of poultry, though no international trade restrictions apply; nonetheless, national veterinary authorities should incorporate CIAV into comprehensive poultry health programmes.

Biosecurity and Management-Based Interventions

Given that CIAV is highly resistant to common disinfectants and can persist in poultry houses, equipment, and litter for extended periods [11, 14], biosecurity forms the cornerstone of prevention. Complete depopulation, thorough cleaning, and disinfection with peracetic acid or chlorine-based compounds, followed by a downtime of at least 14–21 days, are recommended to break the cycle of environmental contamination. Vertical transmission via the egg from infected breeders to progeny is a major route of early exposure [10, 22]; therefore, hatchery sanitation and the use of eggs only from seropositive, vaccinated breeder flocks are critical. The high seroprevalence observed in both commercial and village chickens across multiple countries, 68.2% in Nigeria [3], 87.5% in Sri Lankan village chickens [4], and 65.4% in Chinese broilers [5], underscores the widespread circulation of the virus and the need for robust biosecurity even in regions where vaccines are used. Co-infections with immunosuppressive agents such as Marek’s disease virus (MDV), infectious bursal disease virus (IBDV), fowl adenoviruses (FAdV), and avian influenza H9N2 are well documented and exacerbate disease severity [2, 7, 16, 24-26]. Consequently, biosecurity protocols must also target these concomitant pathogens to prevent synergistic immunosuppression and vaccination failures.

Vaccination as a Central Pillar of Control

Maternal Antibody Transfer and Breeder Vaccination

The most cost-effective and widely adopted strategy is the vaccination of broiler and layer breeders to induce high levels of maternal antibodies that protect progeny during the first two to three weeks of life [14, 22]. Field evaluations have demonstrated that commercial live-attenuated CIAV vaccines administered to breeders at around 14 weeks of age elicit ELISA titres ranging from 5,051 to 8,660, with an average transfer rate of 63% to progeny. These maternal antibodies typically persist for up to 14 days post-hatch, shielding chicks from early vertical and horizontal infection [22]. Without effective breeder vaccination, young chicks remain vulnerable to the classic clinical triad of anaemia, haemorrhages, and gangrenous dermatitis [10, 25]. In Taiwan, where breeder vaccination is routine, clinical CIA still occurs, often due to antigenic drift or vaccine-like strains reverting to virulence [21]. This highlights the need for periodic reassessment of vaccine efficacy against circulating field strains.

Live Attenuated and Vectored Vaccines

Currently available commercial live-attenuated CIAV vaccines (e.g., 26P4, Del-Ros, and several Chinese and Korean strains) provide robust protection when administered via drinking water or injection. However, reversion to virulence has been documented; vaccine-like isolates have been recovered from clinical cases in Taiwan and China, suggesting that improper handling or back-passage in the field can increase pathogenicity [21]. Furthermore, some vaccine strains do not cluster with predominant field genotypes. For instance, in Korea, none of the circulating CIAV strains grouped with the local vaccine strain [10], and in Vietnam, all field isolates lacked attenuation markers and belonged to genogroups G2 and G3, distinct from vaccine-like viruses [6]. Such discrepancies underscore the importance of genotype-matching in vaccine selection.

A promising alternative is the development of recombinant vectored vaccines. Chellappa et al. [8] engineered a bivalent Newcastle disease virus (NDV) vector expressing CIAV VP1 and VP2 proteins. This live-vectored candidate (rR2B-FPCS-CAV) induced strong humoral and cell-mediated immune responses in specific-pathogen-free (SPF) chicks, significantly reduced NDV shedding, and protected against CIAV challenge as measured by haematological parameters (PCV, TLC, PLC). The use of an NDV vector offers dual protection and eliminates the risk of CIAV reversion. Such platforms may be particularly advantageous in regions where both NDV and CIAV are endemic.

Molecular Surveillance and Diagnostic Tools for Targeted Control

Accurate and early detection of CIAV is essential for both biosecurity decisions and evaluating vaccination success. Traditional serology (ELISA) is useful for flock-level screening, as demonstrated in seroprevalence studies in Nigeria, Sri Lanka, and India [3, 4, 17], but cannot distinguish vaccine-induced antibodies from natural infection. PCR-based methods, including conventional PCR targeting the VP1 or VP2 genes, real-time qPCR, and isothermal amplification, offer higher sensitivity and can detect viral DNA before seroconversion [23, 29]. A multiplex fluorescence loop-mediated isothermal amplification (mLAMP) assay developed by Fan et al. [23] simultaneously detects CIAV, chicken parvovirus, and FAdV-4 with a detection limit of 749 copies of CIAV plasmid DNA and 100% agreement with PCR on field samples. This technique is rapid, does not require expensive thermocyclers, and is therefore suitable for rural and resource-limited settings.

Quantitative real-time PCR has also been used to monitor viral load dynamics in experimental and field infections. Vagnozzi et al. [29] showed that CIAV genome can be detected in invasive (thymus, bone marrow) and non-invasive (feather pulp, cloacal swabs) samples as early as 7 days post-inoculation, whereas seroconversion is delayed until 14 days. This window allows early intervention, such as isolation of affected flocks or postponement of stressful procedures (e.g., vaccination against other diseases). In SPF flocks used for vaccine production, routine qPCR monitoring is mandatory because maternal antibodies can mask seropositivity while virus persists in lymphoid tissues [29]. The use of such molecular tools should be integrated into national surveillance programmes, as recommended by the FAO’s guidelines for transboundary animal diseases.

Immunomodulation and Supportive Therapy

In the absence of specific antiviral drugs for CIAV, supportive therapy, particularly in broilers where maternal immunity is insufficient, can mitigate disease severity. Nutritional supplementation with protein, vitamins, and selenium has been shown to improve haematological and immunological parameters in CIAV-infected chicks. Krishan [30] demonstrated that a commercial supplement (Multimune) containing protein, vitamins, and selenium, fed at 1 g per 10 birds for three weeks, significantly reduced anaemia, increased total leukocyte counts, enhanced Newcastle disease antibody titres, and improved body weight gains compared to untreated infected controls. The proposed mechanism involves selenium’s role in glutathione peroxidase activity, reducing oxidative stress associated with CIAV-induced apoptosis, while protein and vitamins support lymphocyte proliferation.

Although such immunomodulators do not clear the virus, they can limit secondary infections and reduce mortality, an important consideration in village poultry systems where vaccination coverage is low [4, 30]. Furthermore, minimising stress factors (overcrowding, poor ventilation, concurrent vaccinations) is critical, as CIAV-induced immunosuppression is exacerbated by environmental triggers.

Control of Co-Infections and Vaccination Failures

CIAV’s immunosuppressive nature predisposes birds to a wide range of secondary viral and bacterial pathogens. Field surveys consistently report that the majority of CIAV-positive flocks suffer from concurrent infections: 55.56% in Chinese clinical cases [19], 45.8% with MDV in Nigeria [2], and high rates with IBDV [24], FAdV [7], and bacteria causing gangrenous dermatitis [25]. To prevent such synergistic disease, control programmes must simultaneously target these co-pathogens. For example, vaccination against MDV should be complemented by CIAV control to ensure full efficacy; indeed, Adedeji et al. [2] found that 100% of broilers with MDV-CIAV co-infections had severe clinical disease despite MD vaccination. Similarly, outbreaks of inclusion body hepatitis in Trinidad were linked to FAdV serotypes 8a, 8b, 9, and 11 in association with CIAV [7], emphasising the need for FAdV-specific vaccines in areas where both viruses circulate.

A critical consequence of CIAV co-infection is vaccination failure against other diseases. The virus depletes CD4+ and CD8+ T lymphocytes [13], downregulates cytokines such as IL-1β, IL-2, IL-12, and IFN-γ [11, 15, 28], and impairs germinal centre formation in the bursa. This leads to suboptimal antibody responses to routine vaccines (e.g., NDV, IBDV) [16, 26, 30]. Therefore, any unexplained poor vaccine performance should prompt investigation of underlying CIAV infection. Control strategies must include comprehensive diagnostic panels that incorporate CIAV alongside other immunosuppressive agents.

Genetic Diversity and the Need for Updated Vaccines

CIAV exhibits considerable genetic variability, especially in the capsid protein VP1, which is the primary target of neutralizing antibodies. Phylogenetic analyses have identified multiple genotypes (I–IV, with subclades IIa, IIb, IIIa, IIIb) circulating globally, and recombination events contribute to ongoing evolution [5, 10, 11, 19, 21]. In China, genotype IIIa predominates [5], while in Korea groups IIb, IIIa, and IIIb are equally represented [10]; Taiwan harbours a novel genotype IV derived from inter-genotypic recombination [21]. Importantly, field isolates often lack the attenuation-associated amino acid substitutions found in vaccine strains, suggesting that vaccine-driven immunity may be suboptimal against heterologous strains [6, 21]. For instance, the Korean study reported that none of the circulating strains clustered with the local vaccine, and in vivo challenge demonstrated that all major genotypes (IIb, IIIa, IIIb) induced severe anaemia, growth retardation, and immunosuppression [10].

These findings strongly support the need for periodic molecular epidemiological surveys and, if necessary, the development of multivalent or chimeric vaccines that cover regional circulating genotypes. Regulatory bodies such as the WOAH should encourage member countries to submit CIAV sequence data to public databases to facilitate global monitoring. Additionally, research into apoptin (VP3)-based reverse genetics may enable rational attenuation of virulent strains for use as modified live vaccines, although safety must be rigorously validated.

Final Considerations for National Control Programmes

A comprehensive CIAV control strategy must be multi-layered: (1) breeder vaccination to ensure passive immunity in progeny; (2) strict biosecurity including all-in/all-out management, disinfection, and vector control; (3) active surveillance using molecular tools (qPCR, mLAMP) to detect early infection and monitor vaccine efficacy; (4) immunomodulatory support in high-risk flocks; (5) integration with control measures against other immunosuppressive and respiratory pathogens; and (6) genotype-informed vaccine updates to counter emerging variants. The high seroprevalence reported in extensive farming systems [1, 3, 4, 17] indicates that control is particularly challenging in village poultry, where biosecurity is minimal and vaccination rare. Extension services and public-private partnerships, as advocated by FAO and WOAH, are needed to deliver affordable vaccines and diagnostic services to smallholder farmers.

In conclusion, the control of CIAV is not solely a matter of vaccination, it demands a holistic approach that acknowledges the virus’s ubiquity, environmental persistence, immunosuppressive synergy, and genetic plasticity. Only through sustained surveillance, evidence-based vaccination, and robust biosecurity can the poultry industry mitigate the substantial economic burden imposed by chicken infectious anaemia.

References

[1] Shettima Y, Gambo H, Hamisu T, El-Yuguda AA, Abubakar M, Sajo M. Molecular characterization of chicken infectious anaemia virus isolated from village chickens in Maiduguri, Nigeria. Sokoto Journal of Veterinary Sciences. 2025. DOI: https://doi.org/10.4314/sokjvs.v22i4.4

[2] Adedeji A, Shittu I, Akanbi O, Asala O, Adole J, Okewole P, et al.. First report of co-infections of Marek's disease virus and chicken infectious anaemia virus in poultry flocks in Nigeria. Veterinary and Animal Science. 2024. DOI: https://doi.org/10.1016/j.vas.2024.100339

[3] Markus T, Adamu J, Abdu P, Orakpoghenor O, Kazeem H, Idoko F. Exploring Seroprevalence Variations of Chicken Infectious Anaemia Virus in Local and Exotic Chickens within Jos, Plateau State, Nigeria. Journal of Research in Veterinary Sciences. 2024. DOI: https://doi.org/10.5455/jrvs.20240615012337

[4] Hassim F, Jayawardhana EGNH, Ekanayaka W, Jayawardana YK, Amarasena S, Gunawardana T, et al.. Point Seroprevalence of Chicken Anaemia Virus and Infectious Laryngotracheitis Virus in Village and Commercial Poultry Systems in Selected Areas of Central and North Western Provinces of Sri Lanka. Sri Lanka Veterinary Journal. 2025. DOI: https://doi.org/10.4038/slvj.v72i2.110

[5] Sun H, Yu S, Jiang T, Yan Z, Wang D, Chen L, et al.. Molecular characterization of chicken infectious anaemia virus (CIAV) in China during 2020–2021. Avian Pathology. 2022. DOI: https://doi.org/10.1080/03079457.2022.2155109

[6] Huynh LTM, Nguyen GV, Do L, Dao TD, Le TV, Vu NT, et al.. Chicken infectious anaemia virus infections in chickens in northern Vietnam: epidemiological features and genetic characterization of the causative agent. Avian Pathology. 2020. DOI: https://doi.org/10.1080/03079457.2019.1637821

[7] Jordan AB, Blake L, Bisnath J, Ramgattie C, Carrington C, Oura C. Identification of four serotypes of fowl adenovirus in clinically affected commercial poultry co-infected with chicken infectious anaemia virus in Trinidad and Tobago.. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13162

[8] Chellappa MM, Dey S, Pathak D, Singh A, Ramamurthy N, Ramakrishnan S, et al.. Newcastle Disease Virus Vectored Chicken Infectious Anaemia Vaccine Induces Robust Immune Response in Chickens. Viruses. 2021. DOI: https://doi.org/10.3390/v13101985

[9] Brar R, Bahnot V, Mahajan N, Tomar P, Prakash AK, Maan S. Detection and molecular characterization of chicken infectious anaemia virus in poultry flocks in Haryana. Indian Journal of Animal Sciences. 2020. DOI: https://doi.org/10.56093/ijans.v89i12.96620

[10] Song H, Kim H, Kwon Y, Kim H. Genetic characterization of chicken infectious anaemia viruses isolated in Korea and their pathogenicity in chicks. Frontiers in Cellular and Infection Microbiology. 2024. DOI: https://doi.org/10.3389/fcimb.2024.1333596

[11] Karki M, Bora M, M M, Kumar A. An updated review on chicken infectious anaemia. Worlds Poultry Science Journal. 2024. DOI: https://doi.org/10.1080/00439339.2024.2416682

[12] Latheef SK, Dhama K, Samad HA, Sachan S, Sruthi S, Kumar A, et al.. COMPARATIVE EVALUATION OF APOPTOSIS INDUCED CHANGES IN THYMOCYTES OF SPF CHICKS CO-INFECTED WITH CHICKEN INFECTIOUS ANAEMIA VIRUS (CIAV) AND MAREK’S DISEASE VIRUS (MDV). Journal of Experimental Biology and Agricultural Sciences. 2019. DOI: https://doi.org/10.18006/2019.7(4).418.422

[13] Wani M, Dhama K, Tiwari R, Barathidasan R, Malik Y, Singh S, et al.. Immunosuppressive effects of chicken infectious anaemia virus on T lymphocyte populations using flow cytometry and hematological parameters during experimental subclinical infection in chicks.. Advances in Animal and Veterinary Sciences. 2015. DOI: https://doi.org/10.14737/JOURNAL.AAVS/2015/3.3.143.150

[14] Gerish AIAEK. Chicken Infectious Anaemia Virus: A Mini-Review. Journal of Pure & Applied Sciences. 2019. DOI: https://doi.org/10.51984/jopas.v18i3.222

[15] Basaraddi MS, Dhama K, Wani M, Tiwari R, Kumar D, Singh S, et al.. Downregulation in cytokines profiles and immunopathological changes in chicks infected with chicken infectious anaemia virus. African Journal of Microbiology Research. 2013. DOI: https://doi.org/10.5897/AJMR2012.2357

[16] Krishan G, Shukla S, Bhatt P, Wani M, Dhama K, Malik Y, et al.. Clinical Association of Chicken Anaemia Virus with Other Infectious Poultry Diseases in North India and Nepal: Its Pathological Studies, Molecular Epidemiology and RFLP Pattern of PCR Amplified Full Length Viral Genome. Advances in Animal and Veterinary Sciences. 2015. DOI: https://doi.org/10.14737/JOURNAL.AAVS/2015/3.7.395.405

[17] Vidya P, Sankar S, Mini M, Priya PM, Sajitha I. Investigation on the prevalence of chicken anaemia virus in poultry flocks of Kerala, India. Journal of Veterinary and Animal Sciences. 2023. DOI: https://doi.org/10.51966/jvas.2023.54.3.687-692

[18] Hristova M, Simeonov K. Chicken Infectious Anaemia and Co-Infections. Approaches in Poultry, Dairy & Veterinary Sciences. 2018. DOI: https://doi.org/10.31031/apdv.2018.05.000604

[19] Yao S, Tuo T, Gao X, Han C, Yan N, Liu A, et al.. Molecular epidemiology of chicken anaemia virus in sick chickens in China from 2014 to 2015. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0210696

[20] Castaño P, Benavides J, Lee M, Fernández M, Fuertes M, Royo M, et al.. Tissue Tropism of Chicken Anaemia Virus in Naturally Infected Broiler Chickens.. Journal of Comparative Pathology. 2019. DOI: https://doi.org/10.1016/j.jcpa.2018.11.008

[21] Ou S, Lin H, Liu P, Huang H, Lee M, Lien Y, et al.. Epidemiology and molecular characterization of chicken anaemia virus from commercial and native chickens in Taiwan. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.12886

[22] Rodrigues E, Imperatori F, Back A, Kuana S, Brehmer M. Rate of Transfer of Infectious Anaemia Maternal Antibodies from Broiler Breeders To the Progeny: a Field Evaluation. Brazilian Journal of Poultry Science. 2022. DOI: https://doi.org/10.1590/1806-9061-2021-1562

[23] Fan Q, Xie Z, Zhang Y, Xie Z, Xie L, Huang J, et al.. A multiplex fluorescence-based loop-mediated isothermal amplification assay for identifying chicken parvovirus, chicken infectious anaemia virus, and fowl aviadenovirus serotype 4. Avian Pathology. 2023. DOI: https://doi.org/10.1080/03079457.2022.2159326

[24] Shettima YM, Hamisu T, Sajo MU, Gambo H, Abubakar M, El-Yuguda A. Concurrent Infections of Poultry with Chicken Infectious Anaemia and Infectious Bursal Disease Viruses in Maiduguri, Nigeria: A Seroprevalence Study. Sahel Journal of Veterinary Sciences. 2025. DOI: https://doi.org/10.54058/bj2szd61

[25] Suohu S, Balasubramaniam G, Arulmozhi A, Gopalakrishnamurthy T, Raja A. Pathological studies on chicken infectious anaemia and concurrent infections in layer flocks of Namakkal, Tamil Nadu. Indian Journal of Animal Sciences. 2024. DOI: https://doi.org/10.56093/ijans.v94i9.144412

[26] Erfan A, Selim A, Helmy SA, Eriksson P, Naguib M. Chicken anaemia virus enhances and prolongs subsequent avian influenza (H9N2) and infectious bronchitis viral infections.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.01.024

[27] Neama A, Alaraji F, Al-Aqaby AA, Al-ibadi IA. A review. blue Wing Disease -chicken infectious anaemia molecular study. Kufa Journal For Veterinary Medical Sciences. 2020. DOI: https://doi.org/10.36326/kjvs/2019/v10i13322

[28] Wani M, Dhama K, Latheef SK, Singh S, Tiwari R. Correlation between cytokine profile, antibody titre and viral load during sub-clinical chicken anaemia virus infection.. Veterinarni Medicina. 2018. DOI: https://doi.org/10.17221/7244-VETMED

[29] Vagnozzi A, Espinosa R, Cheng S, Brinson D, O’Kane P, Wilson JL, et al.. Study of dynamic of chicken infectious anaemia virus infection: which sample is more reliable for viral detection?. Avian Pathology. 2018. DOI: https://doi.org/10.1080/03079457.2018.1492089

[30] Krishan G. Immunomodulatory and Therapeutic Prospective of a Protein Supplement with Vitamins and Selenium (Multimune) against Chicken Infectious Anaemia in Broiler Chicks. Advances in Animal and Veterinary Sciences. 2015. DOI: https://doi.org/10.14737/JOURNAL.AAVS/2015/3.3S.1.8